The Toxic Effect of Silibinin and Paclitaxel Combination on Endometrial Cancer Cell Line

Background & objectives: Among gynecologic malignancies, endometrial cancer is the fourth most frequent cause of cancer death all over the world. Paclitaxel is one of the chemotherapy regimens that is used against this cancer. Treatment of tumor with Paclitaxel induces apoptosis, but it is also associated with serious side effects. Thus, it is imperative to search for more effective and safer chemotherapeutic regimens. Silibinin is a milk thistle plant extract that its antioxidant effects against some cancers have been studied. The aim of this study was to examine the effect of Paclitaxel and Silibinin combination on endometrial cancer cell line (Hela). Methods: Hela cell line was cultured in 25cm2 flask in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS). Then the numbers of live cells were calculated with trypan blue staining method and then the cells were seeded in to 96-well flat-bottomed culture plates and treated with Silibilin, Paclitaxel and Paclitaxel plus Silibilin together with the control without treatment. MTT assay was used to evaluate cytotoxicity of different treatments. Results: After 48 hours of treatment, Paclitaxel and Silibilin combination inhibited cell growth significantly compared with the other groups (p<0.05). Conclusions: It is indicated that combination of Paclitaxel and Silibilin can affect the growth arrest of Hela cancer cell line more&nbsp; effective than other treatments and is needed to be examined in vitro